Skip to main content

Efficacy

1
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

BioDlink
BioDlinkChina - Jiangsu
1 program
1
TAB008Phase 31 trial
Active Trials
NCT05427305Completed549Est. Mar 2020
Baxter International
1 program
AMIA with SHARESOURCE Connectivity PlatformN/A1 trial
Active Trials
NCT04002440Active Not Recruiting28Est. Apr 2022
Baxter
BaxterCosta Rica - Cartago
1 program
AMIA with SHARESOURCE Connectivity PlatformN/A
Takeda
TakedaTOKYO, Japan
1 program
NiraparibPHASE_21 trial
Active Trials
NCT06237205Not Yet Recruiting33Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BioDlinkTAB008
TakedaNiraparib
Baxter InternationalAMIA with SHARESOURCE Connectivity Platform

Clinical Trials (3)

Total enrollment: 610 patients across 3 trials

NCT05427305BioDlinkTAB008

TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer

Start: Oct 2017Est. completion: Mar 2020549 patients
Phase 3Completed
NCT06237205TakedaNiraparib

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Start: Feb 2024Est. completion: Jun 202733 patients
Phase 2Not Yet Recruiting
NCT04002440Baxter InternationalAMIA with SHARESOURCE Connectivity Platform

Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight

Start: Nov 2018Est. completion: Apr 202228 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.